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ABSTRACT!
!
DNA copy number aberrations (CNAs) can be found in the majority of cancer genomes, 
and are crucial for understanding the potential mechanisms underlying tumor initiation and 
progression. Since the first release in 2001, the Progenetix project (http://
www.progenetix.org) has provided a reference resource dedicated to provide the most 
comprehensive collection of genome-wide CNA profiles. Reflecting the application of 
comparative genomic hybridization (CGH) techniques to tens of thousands of cancer 
genomes, over the past 12 years our data curation efforts have resulted in a more than 60-
fold increase in the number of cancer samples presented through Progenetix. In addition, 
new data exploration tools and visualization options have been added. In particular, the 
gene specific CNA frequency analysis should facilitate the assignment of cancer genes to 
related cancer types. Additionally, the new user file processing interface allows users to 
take advantage of the online tools, including various data representation options for 
proprietary data pre-publication. In this update article, we report recent improvements of 
the database in terms of content, user interface and online tools.!
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INTRODUCTION!
DNA copy number aberrations are a form of genomic mutations found in the majority of 
individual cancer genomes (1-3). Most cancer types, especially solid tumors, exhibit 
distinct patterns of CNAs that may reveal both shared and distinct evolutionary processes 
in the development of different tumor entities (4-6). Understanding the role CNAs play in 
cancer initiation and progression should help to elucidate these mechanisms of 
oncogenesis (2,7). A subset of genomic rearrangements involves distinct oncogenes and 
tumor suppressors, either through the alteration of gene expression profiles or through the 
formation of oncogenic fusion genes, and directly promote cancer growth and metastasis 
(8-10). In clinical research, CNAs have been successfully employed to distinguish cancer 
subtypes and also been recognized as prognostic markers, with potential applications in 
therapeutic stratification (11,12).!
!
Comparative genomic hybridization (CGH) is a class of in situ hybridization techniques that 
has extensively been used to screen genome-wide copy number aberrations in cancer 
samples (13,14). According to the different substrates, CGH platforms can be divided into 
chromosomal CGH (cCGH) and variants of array CGH (aCGH) (15-17). We apply the term 
“array CGH" broadly to cover all types of arrays resulting in whole genome copy number 
status data, including genomic single color arrays (e.g. SNP arrays), for which external 
reference data is used. For cCGH, normal metaphase chromosomes from cultured cells 
are used as hybridization target (13). In aCGH platforms, an array of defined DNA 
fragments is either spotted on a substrate (i.e. glass slide) through a variety of "printing" 
techniques, or is generated through in situ synthesis of DNA oligonucleotides (15,16). For 
all types of hybridization targets, genomic DNA extracted from a tumor sample is 
fluorescencelabeled and hybridized to the denatured target DNA. For dual-color 
experiments (e.g. cCGH, large insert clone arrays), a co-hybridization with normal genomic 
reference DNA labeled with a different fluorochrome is performed; variations in the tumor/
normal fluorescence intensity ratios allow the detection of abnormal genomic content in the 
tumor at the corresponding genome loci (18-20). Single color array experiments require a 
computational evaluation of the signal distribution in relation to external reference datasets 
(21,22). Generally, the resolution of cCGH is limited to chromosome-bands level, and only 
genomic gains and losses greater than approximately 5-10 Mb can be reliably detected by 
cCGH (13). For aCGH, the resolution is determined by the number and size of probes on 
!2
the array (23). Recently, several ultra- high resolution aCGH platforms have been 
manufactured with millions of probes on a single glass chip with the ability to detect minute 
genomic aberrations, as small as a few kb (24,25). These platforms include array types 
originally designed for other purposes, such as single nucleotide polymorphism (SNP) 
arrays and DNA methylation arrays (17,26).!
!
The development of CGH and related techniques has greatly stimulated interest in 
cytogenetic analysis of different cancers (4,27-29). In the last decade, numerous 
oncogenomic data sets have been accumulated, making large-scale analysis across 
multiple cancer entities feasible. For instance, while our group previously had provided a 
descriptive analysis of more than 5000 CGH profiles from epithelial neoplasias (30), 
Beroukhim reported a study of copy number profiles of more than 3000 cancer samples, 
mainly from 26 entities (31). In 2013, Kim presented an analysis based on about 8000 
genomic arrays (32). These analyses exemplified the value of large-scale CNA data 
analysis in cancer research. Furthermore, the comprehensive collection of genomic copy 
number profile scan be used to explore relatively low frequency gene-specific CNAs as 
well as complex events in cancer genomes, such as chromothripsis-like patterns (33,34).!
!
Given the large amount of CGH data scattered in publications and various data 
repositories, it is highly desirable to have a single, comprehensive and well-annotated 
cancer CNA data resource. The Progenetix database aims to provide this kind of service to 
the research community (35). Chromosome and array CGH data in the full-text or 
supplementary files of published papers are extracted, processed and stored in the 
database in a standard format (36). Increasingly, data processed from raw probe files as 
part of the arrayMap project is added after supervised analysis and data review (37). In 
contrast to arrayMap with its representation of probe intensity data, Progenetix captures 
the robust, qualitative aspects of CNA (mapping and directionality), without attempts 
towards fine-grained interpretation of CNA magnitude or interpretation of absolute copy 
numbers.!
!
Other resources for annotated CGH data include NCBI SKY/M-FISH and CGH (38), The 
Cancer Genome Atlas (TCGA) (29), CanGEM (39), CaSNP (40) and arrayMap (37). Each 
of these databases focuses on particular data sources or techniques, and provides unique 
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features. So far, the Progenetix database represents the quantitatively largest resource for 
annotated CNA data from whole genome profiling experiments in cancer (35). As a result 
of over 12 years of data curation, the database currently contains over 30000 individual 
CNA profiles from several hundreds of cancer types. Moreover, it provides a wealth of 
associated clinical information curated from publication texts or supplementary data files.!
!
Here, we describe recent feature updates and relevant improvements of the Progenetix 
resource, and demonstrate the novel data visualization interface and online analysis tools 
that have been added since the database was released 12 years ago.!
!
!
12-YEAR DATA GROWTH!
At the time of the original publication of the Progenetix resource in 2001, our website 
represented a first effort to provide a single resource for accessing whole genome copy 
number profiling data from CGH experiments (35). The database contained a total of 490 
cases collected from 19 publications. The basic inclusion criteria were a) whole genome 
CNA data from b) cancer or pre-malignant samples and c) presented in peer-reviewed 
publications. In contrast to other resources, e.g. the SKY/M-FISH and CGH database then 
under preparation at the NCBI (38,41), Progenetix was intentionally designed as a curated 
database without user driven upload and data manipulation options. Although many 
quantitative and qualitative improvements having been implemented over the years, these 
basic design decisions have remained in place.!
!
The latest release of Progenetix (July 2013) now presents 30687 samples from 1006 
publications, representing a more than 60-fold data expansion compared to the resources 
initial state. Each sample presents the whole-genome copy number profile of an individual 
specimen (DNA from a cancer or leukemia sample or cell line). Included in the data set are 
10261 CNA profiles generated by genomic array experiments, while the remaining are 
based on chromosomal CGH. Currently, samples in Progenetix have been classified into 
363 cancer types according to the International Classification of Diseases in Oncology, 3rd 
Edition (ICD-O 3) (42). Table 1 lists the summary of database content classified by disease 
locus.!
!
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The dramatic increase in data content is primarily the result of the continuous expansion of 
published studies containing CGH based data. To ensure a complete identification of 
articles, we rely on a complex combination of keywords to search PubMed and evaluate 
returned as well as referenced articles with respect to data fromCGH analyses on cancer 
samples. Before the subsequent data extraction step, these studies must fulfill two basic 
criteria: i) The results are obtained from a complete whole-genome screening (with or 
without sex chromosomes) and ii) Experiments were on a case-by-case basis (i.e., no 
pooled samples). So far, we have been able to identify 2390 such publications, reporting 
35703 chromosomal CGH and 68546 array based CNA profiling experiments. As the 
survey data indicates, only a minority of all identified articles contain accessible case-level 
data. Frequently, the authors provide only summary results or describe the copy number 
alterations in selected genes or regions of interest, instead of providing the sample specific 
whole genome CNA data generated through their experiments.!
!
If sample specific CNA data is available, a variety of formats can be encountered, such as 
plain text description in ISCN (43) related formats or based on “Golden Path” coordinates. 
Data in supplementary materials of array based studies is frequently given as probe 
specific normalized log2 ratios. For the sake of convenience of storage and analysis of 
CGH data from different formats, a data processing and collection pipeline was 
established with the final format being the "Golden Path" mapped copy number status 
information of imbalanced genomic regions. ISCN style data is converted using a 
dedicated, regular expression based engine, while for array probe based data sets (e.g. 
raw CEL files or log2 value tables) standard segmentation and thresholding methods are 
being employed (for details pls. refer to (37)).!
!
Besides the absolute content of the database with respect to the number of individual 
records, the information depth of associated data has been extended greatly. While 
originally clinical data was limited to the consistently available diagnostic classification and 
sample locus information, we recently put emphasis on extracting other types of clinical 
data with possible relevance for the association with genomic features. Publications were 
inspected by the database curators to extract case-level clinical features, including patient 
age, gender, follow-up, survival status, tumor stage, grade, and sample source (e.g. 
primary vs. metastasis, recurrence, cell line). Although these criteria are not consistently 
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available, the vast amount of samples will allow for integration of these associated features 
in analyses of considerable data sets; e.g., the current edition contains 3853 samples with 
complete follow-up/survival data (Supplementary Figure S1).!
!
!
USER INTERFACE!
Representation of copy number aberration data in Progenetix is based on the principles of 
a) aggregation of CNA data for different classification values, and b) active aggregation of 
CNA data for dynamically generated data subsets. Pre-defined data categories with 
automatic one-click data aggregation are publications (defined by PMIDs), ICD-O 3 
morphologies (ICD-O 3 codes), disease loci (ICD topography codes) and SEER 
(Surveillance, Epidemiology and End Results) categories (44). Additionally, for the majority 
of cases we have assigned a value for a category called "Clinical Groups" (see below).!
!
Of the different categories, publications have a special place since we also present 
publication entries for articles with discussion of CGH data sets but without corresponding 
samples in the database (e.g. no sample specific data is listed or deposited). The "Search 
Publications" page contains the following input fields: (i) Author Name; (ii) Title Keyword: 
search for keyword occurrence in publication titles; (iii) Text Search: search for keyword 
occurrence in title, author, journal and abstract; (iv) PubMed IDs. In addition, filtering is 
available to (i) select only publications with data in Progenetix and (ii) to limit publications 
to those containing cases generated by aCGH, cCGH or both platforms.!
!
Active data aggregation!
While earlier editions of the Progenetix resource relied on fixed categories with pre-
computed CNA frequency profiles, the current version is based on sample specific data 
with dynamic search and aggregation options. Samples can either be retrieved using ab 
novo queries, or can be selected based on the categories above. Each option leads to a 
second selection step, in which all values existing in the currently active data subset are 
presented for an extended list of categories, allowing for further selection-based restriction 
of the data before processing and visualization.!
!
For the ab novo data retrieval, the "Search Samples" form has options to query for: (i) 
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Text: free text search over most fields; (ii) ICD-O-3 Code: full or partial (start-anchored); 
(iii) ICD Topography Code: full or partial; (iv) PMID; (v) Sample IDs; (vi) Array Series IDs, 
e.g. GEO "GSE"; (vii) Sample Source: metastasis, cell line and primary tumor. Other 
selectors include "Technique" (aCGH vs. cCGH) and the option to only display data with 
completed clinical follow-up. All these search fields can be combined using boolean AND 
(intersection) or boolean OR (union) mode.!
!
For the new version of Progenetix, one noteworthy feature is given through "Find CNAs by 
Gene or Region", which is particularly useful for gene specific queries. Gene names, 
chromosome bands or regions of interest can be specified, and tumor samples with CNAs 
in the queried genomic regions will be returned. Such analysis may be able to pinpoint 
cancer genes that are disturbed and may have a causative relationship to the 
corresponding cancer. The input box suggests plausible gene names and supports auto- 
completion. Moreover, the type of copy number alterations, gain, loss or both, can be 
specified.!
!
As an example usage scenario, here we use the interface to explore data related to 
carcinomas of the esophagus. We start by using the keyword "esophagus" in the "Text 
Search". 475 samples are returned and presented on the "Sample Selection" page (Figure 
1A). In this page, the search results can further be filtered to present only samples fulfilling 
selected criteria. Clicking on the "Sample Details" button will present the list of all samples 
with detailed information, such as clinical data and links to PubMed and/or GEO datasets, 
where available. In the following section of the page, several selector fields provide the 
corresponding values encountered in these 475 samples. Items in these blocks can be 
selected for the next analysis step. In this example, categories include: (i) Article: the 
samples were derived from 22 publications; (ii) Morphology: 8 ICD-O-3 types are 
displayed; (iii) Locus: 2 tumor sites are presented; (iv) Clinical Groups and SEER groups; 
(v) Sample Source; (vi) Technique. Additional options to subset the data are again (vii) 
Find CNAs by Gene or Region and the possible restriction to samples with (viii) Clinical 
Data.!
!
After the "sample selection" step, the resource advances to the "Data Selection and 
Visualization Options" page (Figure 1B). The purpose of this interface is to selectively 
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customize plot options and parameters. Of the parameters, we here only want to mention 
the possibility to restrict CNAs only to such of a given size range (e.g. excluding all whole-
chromosome changes) with a "Segment Size Filter"; the labeling of regions of interest 
using a gene selector or free Golden Path coordinate entry in "Mark Region or Gene 
Locus"; the adjustment of histogram plot parameters such as plot size, range and labeling 
in "Histogram Plot Options" as well as the type of data clustering method and sample 
display. For complex data sets, one helpful option is the "Group Analysis" feature. As 
example, when used in the esophagus ca. data set, setting the value to 
"ICDMORPHOLOGY" and requiring a minimal group number of 50 will produce additional 
CNA histograms for both adenocarcinomas and squamous cell carcinomas of the 
esophagus, as well as a small heatmap presenting the CNA frequencies of those groups 
side-by-side (Supplementary Figure S2).!
!
Another option in this section is to generate both group specific as also locus related 
Kaplan-Meier plots for samples with follow-up data. This option may be used to explore the 
possible association of regional CNAs and clinical risk, as a preliminary step for proper 
gene specific risk attribution.!
!
Although at this time we do not attempt to provide the infrastructure for hosting of user 
generated analysis results, a basic framework is given to generate named, temporary 
directories. This provides users with the option to define a protected directory in which to 
save intermediate analysis results. Detailed instructions on how to navigate the website 
are available in the "FAQ & Guide" page: http://www.progenetix.org/cgi-bin/reader.cgi?
project=progenetix&tags_m=guide.!
!
!
Pre-defined data organization!
Additionally to the ab novo sample selection, the contents of Progenetix can be browsed 
through pre-defined cancer groups as classified by ICD-O-3 coding system, tumor site, 
clinico-pathological entities and SEER (44), respectively. These groups allow users to 
quickly access data for a specific cancer type. At the moment, the most comprehensive 
and detailed standard for cancer classification is ICD-O 3 (International Classification of 
Diseases for Oncology, 3rd Edition) (42). It is a coding system developed by the World 
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Health Organization (WHO) and describes entities based on tumor site (topography) and 
histology (morphology). In total, 363 ICD-O 3 entities are recorded in Progenetix, and 
serve as the primary classifier for most analyses. The second standard classifier is based 
on the ICD-O topography code, i.e. the tumor’s site (Table 1). According to this system, all 
database records are categorized to 80 loci; however, this also mirrors the fact that for 
many samples the assignment granularity is limited (e.g. C069 "mouth, NOS" instead of 
e.g. C062 "retromolar area"), and/or that sample sizes for some specific loci are limited, 
leading to assignment to the more general category. The third classification system 
represents clinico-pathological entity groups; essentially, this system captures the 
approximation of standard diagnostic assignments (e.g. "Carcinomas: Colorectal 
Adenoca." for all types of adeno-carcinomas with location in large intestine or rectum). So 
far, 83 diagnostic groups have been defined in Progenetix. The last system is established 
by the Surveillance, Epidemiology and End Results, a public resource for cancer statistics 
or cancer surveillance methods. According to Progenetix data, 70 SEER cancer groups 
are represented in the database.!
!
!
DATA ANALYSIS TOOLS!
!
Data visualization and exploration!
To exemplify the new data visualization interface and the online analysis tools of 
Progenetix, Figure 2 illustrates the results of processing the pinealis region tumor data, 
represented by 27 samples. The first panel of Figure 2 is a circos-style (45) plot that shows 
the frequency and concurrence of all copy number alterations found in pinealis region 
tumors (Figure 2A). The chromosome ideograms are displayed with cytobands, oriented 
from the p-arm of chromosome 1 to the q-arm of chromosome 22 in a clockwise direction 
with centromeres indicated as purple bands. The frequency of genomic gains and losses 
among the 27 samples is presented in the inner circle by yellow and blue areas, 
respectively. If the dataset is of low-complexity, there will be ribbons representing the 
connections between all concurrent in-case imbalances. In the chromosome ideogram 
(Figure 2B) yellow and blue bars with percentage label on the right and left side of the 
chromosome represent the frequency of gains and losses, respectively. The histogram 
shows the CNA frequencies throughout the genome for building a profile of chromosomal 
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rearrangement hotspots (Figure 2C). This figure may be particularly helpful in the genome-
wide identification of copy number imbalance peaks, which may point to genomic loci 
harboring cancer related genes. Sample specific CNAs are displayed in the "matrix plot" 
panel, with hierarchical clustering applied as selected (Figure 2D). In this case, color labels 
point to different values for PubMed ID, ICD morphology and topography and will be 
detailed as "mouseover" event when opening an SVG version of the image.!
!
If several cancer types are selected for this analysis, differences in CNA patterns among 
different cancer types can usually be observed. In the frequency matrix, a black-to-yellow 
gradient is used to indicate the frequency of gains from lowest to highest, while the 
frequency of losses is given by the gradient from black-to-blue (Figure 2E). This matrix is 
particularly helpful when comparing CNA profiles among several cancer groups with the 
intuitive and global view of regional hotspots. The last section is the "Sample Data", listing 
the summary of each sample that included in this analysis (Figure 2F). Clicking on an 
individual record will lead to a page that provides detailed information of the single sample, 
as well as the graphical representation of the samples CNAs.!
!
!
Gene CNA frequencies!
Cancer related genes may play crucial roles in cancer development, and can be classified 
into the two basic types of oncogenes and tumor suppressor genes (8,9). For a number of 
oncogenes (e.g. ERBB2, MYCN, REL, CDK1), functional activation based on a "dose-
effect" due to genomic copy number gains has been shown. Conversely, tumor 
suppressors are characterized by reduced activity and frequently targets of genomic 
deletions (e.g. TP53, CDKN2A/B, RB, APC). When exploring a candidate cancer related 
gene, one of the interesting questions is the frequency of copy number abnormalities 
involving the gene’s locus in different cancer types. In this new release of Progenetix, we 
provide an online tool in the page "Gene CNA Frequencies", to help investigate cancer 
gene status based on the large amount of tumor samples. Users can search for single or 
combined imbalances by selecting gene names from the auto-complete list, or manually 
specify loci (cytogenetic bands or “Golden Path” coordinates) and types of the changes of 
interest. Furthermore, CNAs can be limited to focal events (e.g. smaller than 5Mb), to 
increase the specificity of the required change through the exclusion of large CNAs 
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affecting multiple possible targets. Please note, that this option is somewhat limited due to 
the limited spatial resolution of the cCGH data sets (13) included in Progenetix. The 
"Minimal Case Number" field provides a threshold to improve the reliability of the query 
results through the optional removal of cancer entities with limited sample number. The 
result page indicates a list with subset specific data: (i) the relative number and percentage 
of samples with the hit; (ii) a score value that weighs the hit frequency by the subset’s 
overall genome complexity (hit frequency divided by the average genome CNA coverage 
of  the subset’s samples). Here, higher complexity samples will have a lower score, due to 
the overall high probability to display a hit in any given region. The returned samples can 
be used for further processing and visualization.!
!
!
OTHER IMPROVEMENTS!
!
User file processing!
We provide a "User File Processing" interface for users to take advantage of the online 
tools by uploading their private data. These data can be tab-delimited text file, a pre-
processed JSON data file (e.g. from a previous Progenetix analysis run) or one of a 
number of segmentation file types as generated by genomic array analysis procedures. 
Depending on the file type selected, CNAs may be annotated either using Golden Path 
coordinates and CNA type or value/threshold combinations, or be provided in a 
cytogenetic annotation format (ISCN "ish cgh" style). Uploaded data is processed into the 
standard internal BSON format, and can be retrieved as JSON file for storage or directly 
be processed in the standard visualization pipeline described before.!
!
Although we focus on human cancer genome data, the online visualization and exploration 
tools can be applied to other species. Recently, the Danio rerio genome coordinates have 
been added to the tool to allow for zebrafish genome data processing. This interface is 
easily extendable upon user request.!
!
Additionally to the general curation and representation of cancer CNA data, Progenetix is 
now being used as hosting framework for disease specific project data. We have recently 
started to provide the backbone and data interface for two collaborative projects. The 
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DIPG project focuses on diffuse intrinsic pontine gliomas (46,47). It aims to provide a 
central resource for researchers to investigate genome-wide profiling data from these 
devastating childhood brain tumors as well as from other rare, aggressive pediatric 
gliomas (48,49). A significant amount of data have been submitted into the database by 
collaborators and supporters and was integrated with publicly-available data sets to 
provide a systematic review and meta-analysis of these diseases. The other current 
project is aimed at cutaneous T-cell lymphomas and related, inflammatory skin diseases.!
!
!
Database implementation, formats and API!
The Progenetix site runs on a MongoDB backend in a Unix environment (Apple Mac OS 
X). Data is stored in a sample specific manner, with pre-computed CNA status interval data 
(1Mb resolution) and sample-specific segments (resolution only limited by original analysis 
technique). For data downloads, JSON data files are provided, as well as tab-delimited 
data formats for CNA status matrices and sample annotation files. With a general 
availability since February 2013, Progenetix now provides a query based API for 
programmatic access and image generation. Documentation including query parameters 
and examples as well as relevant updates regarding query constructs and output formats 
can be accessed through the documentation at http://www.progenetix.org/cgi-bin/
reader.cgi?tagsearch_m=api.!
!
!
!
CONCLUSION!
!
Progenetix is a comprehensive, curated oncogenomic database that provides copy 
number aberration data to the human cancer research community. Over the past 12 years, 
the database has undergone an extensive expansion and significant qualitative 
enhancements. Particularly, the database has made the transition from a “cytogenetic" 
resource based on cancer cytogenetic data to an integrated resource incorporating cancer 
genome data from increasing variety of genome analysis techniques. Likewise, many 
ideas of the user interface improvements and data analysis tools have been implemented 
based on suggestions from users. While providing genomic aberration data from the 
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largest range of cancer entities available, in the future we will especially focus on an 
extension of the data model and improved inclusion of associated clinical information, as 
well as a tighter integration with online repositories and array repositories (e.g. http://
www.arraymap.org).!
!
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Table 1. The full complement of Progenetix data summarized by cancer loc!
* NOS, not otherwise specified!
Cancer loci cCGH aCGH Publications
hematopoietic and reticuloendothelial systems 2580 2689 170
lymph nodes 1181 1164 61
breast 1259 1012 65
cerebellum 674 765 59
brain, NOS* 845 497 78
cerebrum 452 749 49
liver 1054 126 56
stomach 977 178 46
skin 889 184 46
connective and soft tissue, NOS 1001 57 63
kidney 723 295 40
large intestine, excl. rectum and rectosigmoid 
junction
572 429 51
ovary 587 146 27
prostate gland 640 95 20
lung and bronchus 441 258 28
nervous system, NOS 421 246 18
urinary bladder 364 223 14
cervix uteri 411 118 17
peripheral nervs incl. Autonomous 290 233 24
esophagus 426 28 22
pancreas 376 50 17
thyroid gland 385 19 17
pleura 311 72 24
bones and joints 325 25 21
Spleen 56 222 11
other 3677 845 237
Total 20917 10725 1006
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FIGURES!
Figure 1. A screenshot of the data selection page showing the new layout of the search fields. (A) 
Sample selection. (B) Data selection and visualization options. In this example, 475 records were 
returned when searching for the keyword “esophagus”.!
Figure 2. Results page of online statistical analysis tools. In this example, 27 pinealis region tumor 
samples have been selected. The functional blocks illustrate the website’s new functionality. (A) 
Circular CNA plot. (B) Histogram of genomic imbalances. (C) Frequency plot across the genome. 
(D) Matrix plot showing case-level copy number aberrations. (E) Frequency matrix. (F) Sample 
details and links to single case visualization. See text for further details.!
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Supplementary Figures
Figure S1. Overall survival curve in 3853 Progenetix cases.
Figure S2. A heatmap of two subtypes of esophagus carcinoma. The numbers in brackets 
are number of cases. Chromosome 1 to 22 and bands are presented on the top of the 
figure.
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